Rosacea Treatment Market Evolving Industry Trends and Key Insights by 2025

[Guide]

The national survey on rosacea was conducted with over 500 patients suffering from rosacea and about 300 dermatologist, the main finding included the patients struggle emotionally and low self-esteem, don’t feel comfortable talking to their physician, and impact their social and psychological life. Economic productivity loss due to skin diseases is increasing at an alarming rate. According to American Academy of Dermatologists (AAD), skin diseases affect not just productivity but confidence levels of patients, creating passive impact on long term work stature. Exemplifying the above point, AAD noted that ~85 Mn Americans were seen by a physician for at least one skin disease in 2013 in the U.S, leading to direct healthcare costs of US$ 75 Bn and loss due to opportunity cost of US$11 Bn. The symptoms of the rosacea, persist for a week and vanishes and then appear after some time. People generally reach out for either self-treatments or prescription support. According to American Academy of Dermatologists, 90% of the people, who seek professional help, tend to show 40-50% improvement within at least three months.

Some of the major players in global rosacea treatment market are Allergan Plc., Galderma S.A., and Valeant Pharmaceuticals International, Inc., Bayer AG, Dermik Laboratories, Inc., Mayne Pharma, Merz Pharmaceuticals GmbH and Others.

Rosacea Treatment Market Evolving Industry Trends and Key Insights by 2025, Find Market Research

Request for Report Sample @ https://www.persistencemarketresearch.com/samples/18793